{4'-[4-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,3]triazol-1-yl]-biphenyl-4-yl}-acetic acid ethyl ester | 1396007-95-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4'-[4-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,3]triazol-1-yl]-biphenyl-4-yl}-acetic acid ethyl ester
• 英文别名: ethyl 2-[4-[4-[4-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]triazol-1-yl]phenyl]phenyl]acetate
• CAS: 1396007-95-6
• 化学式: C₂₈H₂₈N₄O₄
• 分子量: 484.555
• InChiKey: PWBOOVZGKMGZRR-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  95.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  {4'-[4-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,3]triazol-1-yl]-biphenyl-4-yl}-acetic acid ethyl ester 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 11.0h， 以62.4%的产率得到{4'-[4-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,3]triazol-1-yl]-biphenyl-4-yl}-acetic acid
  参考文献：
  名称：

  [EN] N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS
  [FR] COMPOSÉS N-ARYLTRIAZOLE UTILISÉS COMME ANTAGONISTES DE LPAR

  摘要：

  提供以下公式(I)的化合物：以及 pharmaceutically 可接受的盐，其中取代基如说明书所述。这些化合物以及包含它们的药物组合物可用于治疗炎症性疾病和障碍，例如，例如，肺纤维化。

  公开号：

  WO2013189865A1
• 作为产物：
  描述：

  3-(4-bromo-phenyl)-5-methyl-3H-[1,2,3]triazole-4-carboxylic acid 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium phosphate 、 叠氮磷酸二苯酯 、 palladium diacetate 、 三乙胺 作用下， 以 水 、 甲苯 为溶剂， 反应 8.0h， 生成 {4'-[4-methyl-5-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,3]triazol-1-yl]-biphenyl-4-yl}-acetic acid ethyl ester
  参考文献：
  名称：

  [EN] N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS
  [FR] COMPOSÉS N-ARYLTRIAZOLE UTILISÉS COMME ANTAGONISTES DE LPAR

  摘要：

  提供以下公式(I)的化合物：以及 pharmaceutically 可接受的盐，其中取代基如说明书所述。这些化合物以及包含它们的药物组合物可用于治疗炎症性疾病和障碍，例如，例如，肺纤维化。

  公开号：

  WO2013189865A1

文献信息

• [EN] N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS<br/>[FR] COMPOSÉS N-ARYLTRIAZOLE UTILISÉS COMME ANTAGONISTES DE LPAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013189865A1

  公开（公告）日：2013-12-27

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.

  提供以下公式(I)的化合物：以及 pharmaceutically 可接受的盐，其中取代基如说明书所述。这些化合物以及包含它们的药物组合物可用于治疗炎症性疾病和障碍，例如，例如，肺纤维化。
• N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS
  申请人：Hoffmann-La Roche Inc,

  公开号：US20150133512A1

  公开（公告）日：2015-05-14

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.

  本文提供公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露。这些化合物及含有它们的制药组合物可用于治疗炎症性疾病和疾病，例如肺纤维化。
• Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts
  作者：Yimin Qian、Matthew Hamilton、Achyutharao Sidduri、Stephen Gabriel、Yonglin Ren、Ruoqi Peng、Rama Kondru、Arjun Narayanan、Terry Truitt、Rachid Hamid、Yun Chen、Lin Zhang、Adrian J. Fretland、Ruben Alvarez Sanchez、Kung-Ching Chang、Matthew Lucas、Ryan C. Schoenfeld、Dramane Laine、Maria E. Fuentes、Christopher S. Stevenson、David C. Budd

  DOI：10.1021/jm301022v

  日期：2012.9.13

  Lysophosphatidic acid is a class of bioactive phospholipid that mediates most of its biological effects through LPA receptors, of which six isoforms have been identified. The recent results from LPA1 knockout mice suggested that blocking LPA1 signaling could provide a potential novel approach for the treatment of idiopathic pulmonary fibrosis. Here, we report the design and synthesis of pyrazole- and triazole-derived carbamates as LPA1-selective and LPA1/3 dual antagonists. In particular, compound 2, the most selective LPA1 antagonist reported, inhibited proliferation and contraction of normal human lung fibroblasts (NHLF) following LPA stimulation. Oral dosing of compound 2 to mice resulted in a dose-dependent reduction of plasma histamine levels in a murine LPA challenge model. Furthermore, we applied our novel antagonists as chemistry probes and investigated the contribution of LPA1/2/3 in mediating the pro-fibrotic responses. Our results suggest LPA1 as the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF.